Back to User profile » Prof. Dr. Kyung-Sang Yu
Papers published by Prof. Dr. Kyung-Sang Yu:
Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose Combination in Healthy Korean Male Subjects
Khwarg J, Lee S, Jang IJ, Kang WH, Lee HJ, Kim KY, Jeong KS, Won C, Choi YW, Ha DC, Jung R, Han MG, Jung WT, Nam KY, Kim YS, Yu KS, Oh J
Drug Design, Development and Therapy 2024, 18:395-406
Published Date: 8 February 2024
Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
Jiang X, Bae S, Yoon DY, Park SJ, Oh J, Cho JY, Yu KS
Drug Design, Development and Therapy 2023, 17:2137-2145
Published Date: 24 July 2023
Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole
Bae S, Kwon J, Lee MH, Yu KS, Lee S
Drug Design, Development and Therapy 2023, 17:497-506
Published Date: 15 February 2023
Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
Bae S, Kwon J, Lee SB, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:5099-5108
Published Date: 21 December 2021
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
Hwang S, Lee DY, Cho JY, Chung JY, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:2375-2384
Published Date: 1 June 2021
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
Jeon I, Oh J, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:1735-1747
Published Date: 28 April 2021
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
Yang E, Yoo H, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:651-658
Published Date: 17 February 2021
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
Yoo H, Kim Y, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2020, 14:5179-5187
Published Date: 24 November 2020
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
Hwang I, Kim Y, Yoo H, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2020, 14:4493-4502
Published Date: 23 October 2020
Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets
Hwang JG, Yu KS, Lee S
Drug Design, Development and Therapy 2020, 14:1953-1961
Published Date: 20 May 2020
A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
Kim E, Park KR, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2019, 13:3879-3885
Published Date: 13 November 2019
Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects
Moon SJ, Jeon JY, Jang K, Yu KS, Lim Y, Kim MG
Drug Design, Development and Therapy 2019, 13:2533-2542
Published Date: 25 July 2019
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers
Shin D, Park SI, Lee HS, An KM, Jung J, Lee M, Yu KS
Drug Design, Development and Therapy 2019, 13:2483-2490
Published Date: 24 July 2019
Factors influencing insulin sensitivity during hyperinsulinemic-euglycemic clamp in healthy Korean male subjects
Shin D, Eom YS, Chon S, Kim BJ, Yu KS, Lee DH
Diabetes, Metabolic Syndrome and Obesity 2019, 12:469-476
Published Date: 10 April 2019
Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
Choi Y, Lee S, Jang IJ, Yu KS
Drug Design, Development and Therapy 2018, 12:2301-2309
Published Date: 24 July 2018
Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic
Sunwoo J, Kim YK, Choi Y, Yu KS, Nam H, Cho YL, Yoon S, Chung JY
Drug Design, Development and Therapy 2018, 12:1707-1714
Published Date: 11 June 2018
Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu KS, Jang IJ
Drug Design, Development and Therapy 2018, 12:1045-1051
Published Date: 30 April 2018
Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians
Lee J, Rhee SJ, Lee S, Yu KS
Drug Design, Development and Therapy 2018, 12:787-794
Published Date: 6 April 2018
Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects
Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S
Drug Design, Development and Therapy 2018, 12:331-337
Published Date: 19 February 2018
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
Kim S, Lee S, Cho JY, Yoon SH, Jang IJ, Yu KS
Drug Design, Development and Therapy 2017, 11:3187-3195
Published Date: 7 November 2017
A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects
Kim YK, Choi MJ, Oh TY, Yu KS, Lee S
Drug Design, Development and Therapy 2017, 11:3171-3177
Published Date: 6 November 2017
Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
Yoon S, Rhee SJ, Heo SJ, Oh TY, Yoon SH, Cho JY, Lee S, Yu KS
Drug Design, Development and Therapy 2017, 11:3127-3135
Published Date: 27 October 2017
A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers
Lee J, Kim BH, Yu KS, Kim HS, Kim JD, Cho JY, Lee S, Gu N
Drug Design, Development and Therapy 2017, 11:1301-1313
Published Date: 24 April 2017
Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
Shin D, Lee S, Yi S, Yoon SH, Cho JY, Bahng MY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2017, 11:713-723
Published Date: 10 March 2017
Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
Jang K, Kim M, Oh J, Lee S, Cho JY, Yu KS, Choi TK, Lee SH, Lim KS
Drug Design, Development and Therapy 2017, 11:705-711
Published Date: 9 March 2017
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
Suh HY, Peck CC, Yu KS, Lee H
Drug Design, Development and Therapy 2016, 10:4005-4016
Published Date: 8 December 2016
Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
Choi Y, Lee S, Cho SM, Kang WH, Nam KY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2016, 10:3021-3028
Published Date: 20 September 2016
Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, Cho JY, Yu KS
Drug Design, Development and Therapy 2016, 10:2525-2534
Published Date: 10 August 2016
Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
Rhee SJ, Lee S, Yoon SH, Cho JY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2016, 10:1411-1418
Published Date: 13 April 2016
Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
Yoon S, Shin D, Lee H, Jang IJ, Yu KS
Drug Design, Development and Therapy 2015, 9:5033-5049
Published Date: 31 August 2015
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers
Choi YJ, Han HK, Shin D, Lim KS, Yu KS
Drug Design, Development and Therapy 2015, 9:4127-4135
Published Date: 31 July 2015
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
Chung H, Lee H, Han H, An H, Lim KS, Lee YJ, Cho JY, Yoon SH, Jang IJ, Yu KS
Drug Design, Development and Therapy 2015, 9:2609-2616
Published Date: 13 May 2015
Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
Hong T, Han S, Lee J, Jeon S, Park GJ, Park WS, Lim KS, Chung JY, Yu KS, Yim DS
Drug Design, Development and Therapy 2015, 9:1233-1245
Published Date: 26 February 2015
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, Jung JH, Yu KS
Drug Design, Development and Therapy 2015, 9:729-736
Published Date: 4 February 2015
Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
Lee J, Lee H, Jang K, Lim KS, Shin D, Yu KS
Drug Design, Development and Therapy 2014, 8:1781-1788
Published Date: 8 October 2014
Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
Kim S, Lee J, Shin D, Lim KS, Kim YS, Jang IJ, Yu KS
Drug Design, Development and Therapy 2014, 8:1723-1731
Published Date: 6 October 2014
Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2014, 8:1709-1721
Published Date: 6 October 2014
Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
Cha YJ, Lim KS, Park MK, Schneider S, Bray B, Kang MC, Chung JY, Yoon SH, Cho JY, Yu KS
Drug Design, Development and Therapy 2014, 8:1613-1619
Published Date: 26 September 2014
Predictive performance of gentamicin dosing nomograms
Lee J, Yoon S, Shin D, Han H, An H, Lee J, Lim KS, Yu KS, Lee H
Drug Design, Development and Therapy 2014, 8:1097-1106
Published Date: 16 August 2014
Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state
Jang K, Yoon S, Kim SE, Cho JY, Yoon SH, Lim KS, Yu KS, Jang IJ, Lee H
Drug Design, Development and Therapy 2014, 8:851-858
Published Date: 25 June 2014
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ
Drug Design, Development and Therapy 2014, 8:123-128
Published Date: 15 January 2014